Verantos offers RWE solutions that are as advanced as your therapy
Verantos provides clearer insights based on our real-world evidence platform to generate high-validity results. Our approach, which engages health systems directly and utilizes the entire patient record, including unstructured EHR clinical narrative, provides a robust view of the patient journey, including disease severity, treatment, symptom control, and clinical outcome parameters.
The Verantos
solution advantage
Our solutions include the following:
Observational Research
Verantos’ Observational Research solution generates high-validity real-world evidence (RWE) to power life sciences companies’ observational studies. These longitudinal studies are executed using deep phenotyping to support difficult inclusion and exclusion criteria, endpoints, and outcomes.
Pragmatic Registry
Verantos’ Pragmatic Registry enables life sciences companies to subscribe to indication-specific data sets that represent patient cohorts generated using deep phenotyping and linkage. Measurable industry-leading data reliability enabling high-validity evidence generation facilitates clinical assertions to support clinician, payer, and regulator decision-making.
Our solutions advance the state of the art in the following functions.
Market access
- More credible evidence to help payers and health technology assessment (HTA) bodies understand the value of today’s therapies
- High-reliability RWD your teams can use to generate high-validity real-world evidence, which is necessary for credibility in conversations with payers
- Rapid time-to-value, shortening the delay in moving from UM-controlled access to preferred brand tier
Pharmacovigilance
- Pragmatic registries from high-accuracy RWD reduce false positives in potential safety signals
- Better safety contextualization of patients experiencing adverse reactions
- Earlier detection of real-world safety signals from more representative populations to reduce risk of onerous post-marketing studies
Clinical development
- Complete view of the patient journey without the overhead of consented registries
- Patients from community health systems and academic medical centers and provide more representative outcomes
- Larger sample sizes with more granular phenotyping